MedPath

Visirna Therapeutics HK Limited

🇭🇰Hong Kong, China
Ownership
Private
Established
2022-01-28
Employees
-
Market Cap
-
Website

Clinical Trials

7

Active:1
Completed:1

Trial Phases

3 Phases

Phase 1:3
Phase 2:1
Phase 3:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (50.0%)
Phase 3
2 (33.3%)
Phase 2
1 (16.7%)

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of of VSA012 in Subjects with Paroxysmal Nocturnal Hemoglobinuria(PNH)

Not yet recruiting
Conditions
Paroxysmal Nocturnal Hemoglobinuria (PNH)
First Posted Date
2025-02-27
Last Posted Date
2025-02-27
Lead Sponsor
Visirna Therapeutics HK Limited
Target Recruit Count
16
Registration Number
NCT06848296

A Phase I Clinical Study of VSA012 in Healthy Volunteers

Phase 1
Not yet recruiting
Conditions
Healthy Volunteers
Interventions
Drug: Placebo
First Posted Date
2025-01-09
Last Posted Date
2025-01-09
Lead Sponsor
Visirna Therapeutics HK Limited
Target Recruit Count
32
Registration Number
NCT06766929

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of VSA003 in Chinese HoFH Patients

Phase 3
Not yet recruiting
Conditions
Homozygous Familial Hypercholesterolemia (HoFH)
Interventions
Drug: Placebo
First Posted Date
2024-12-02
Last Posted Date
2024-12-02
Lead Sponsor
Visirna Therapeutics HK Limited
Target Recruit Count
45
Registration Number
NCT06712771

A Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of VSA006 in Chinese NASH Patients

Phase 2
Not yet recruiting
Conditions
Nash
Interventions
Drug: Placebo
First Posted Date
2024-03-21
Last Posted Date
2024-03-21
Lead Sponsor
Visirna Therapeutics HK Limited
Target Recruit Count
45
Registration Number
NCT06322628

A Phase 3 Study of VSA001 in Chinese Adults with Familial Chylomicronemia Syndrome

Phase 3
Active, not recruiting
Conditions
Familial Chylomicronemia Syndrome
Interventions
Drug: Placebo
Drug: VSA001 injection
First Posted Date
2023-06-15
Last Posted Date
2025-03-11
Lead Sponsor
Visirna Therapeutics HK Limited
Target Recruit Count
30
Registration Number
NCT05902598
Locations
🇨🇳

Huashan Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.